RARE DISEASE
Behavioral variant of frontotemporal dementia
Behavioral variant of frontotemporal dementia
Behavioral variant of frontotemporal dementia
Synonyms: bv-FTD
Synonyms: bv-FTD
Synonyms: bv-FTD
Drug discovery
3
drugs
With orphan designations
Overview
Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder marked by progressive personality changes, social disinhibition, apathy, loss of empathy, and executive dysfunction due to frontal/temporal lobe atrophy [1][4][6]. Pathology involves tau, TDP-43, or FUS protein aggregates [1][20]. Diagnosis relies on behavioral criteria, neuroimaging, and exclusion of biomarkers for Alzheimer’s disease [1][4]. Symptoms typically emerge between 45-65 years but can occur earlier or later [2][4][7].
Burden
Therapies
Pharmacologic: SSRIs (e.g., citalopram) for disinhibition/compulsions; cautious use of antipsychotics (e.g., quetiapine) for severe agitation [3][8][13].
Non-pharmacologic: Structured routines, caregiver education, occupational/speech therapy, and palliative care planning [3][9][14].
Avoid cholinesterase inhibitors/memantine (ineffective or harmful) [13][20].
Categories: rare genetic diseases, rare neurological diseases
Research Papers
255 drug discovery papers related to Behavioral variant of frontotemporal dementia, with 5 first-in-class and 1 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
255 drug discovery papers related to Behavioral variant of frontotemporal dementia, with 5 first-in-class and 1 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-17 | Diagnosis and management of frontotemporal dementia: a narrative review.
Frontotemporal dementia (FTD) is an umbrella term that encompasses a group of clinically heterogeneous neurodegenerative disorders. It is biologically referred to as Frontotemporal lobar degeneration (FTLD) and is characterized by progressive degeneration of frontal and/or temporal lobes. FTD poses substantial diagnostic and therapeutic challenges due to its heterogeneous clinical presentations, limited biomarker specificity, and overlap with other neurodegenerative and psychiatric diseases. This review synthesizes updated knowledge on the clinical phenotypes of FTD, their prognostic elements, and the underlying genetic and molecular mechanisms. Advances in diagnostic strategies are discussed, including structural and functional neuroimaging, fluid biomarkers, and genetic testing, together with emerging digital and AI-assisted tools that may enhance diagnostic precision. Evidence-based management approaches are examined, alongside the role of multidisciplinary care and caregiver support. Promising therapeutic strategies, including gene-targeted interventions, antisense oligonucleotides, progranulin restoration strategies, immunotherapies, and neuromodulation techniques, are discussed considering recent clinical and preclinical developments. Despite the absence of approved disease-modifying therapies, rapid progress in biomarker development, patient stratification, and personalized approaches offers encouraging prospects for more effective interventions across the FTD spectrum. PubMed/MEDLINE was searched for peer-reviewed articles on FTD diagnosis and management; reference lists of key articles were screened to identify additional sources.
2026-06-04 | Emotion Perception in Behavioral Variant Frontotemporal Dementia and Alzheimer Disease: The Parahippocampal Conundrum.
Emotion perception is the capacity that enables humans to correctly identify the cues that guide interpersonal interactions, forming the basis for social behavior. The parahippocampal cortex may contribute to emotion perception by mediating the associations between context and emotion. Individuals with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) appear to show deficits in this process. Investigating emotion perception impairment in these individuals could offer valuable insights into the underlying neurobiological mechanisms. Participants included a convenience sample of 29 individuals with bvFTD, 25 with AD, and a comparison group of 15 individuals without bvFTD or AD. We performed an extensive neuropsychological assessment and administered the Comprehensive Affect Testing System (CATS) to evaluate the emotion perception process. We then used multiple regression analysis to assess the relationship between CATS main quotient scores and parahippocampal thickness (P ≤ 0.001) obtained from MRI analysis. Participants with bvFTD scored higher on cognitive tests than participants with AD but showed greater deficits in social behavior. On the CATS, participants with bvFTD had lower scores in all 3 emotional quotients (ie, face, prosody, and global), with a statistically significant correlation to parahippocampal thickness. Participants with AD showed milder deficits in all 3 emotion quotients, with no statistically significant correlation to parahippocampal thickness. Our data suggest a significant emotion perception deficit in individuals with bvFTD and support the importance of the parahippocampal gyrus in context-emotion associations. Targeted rehabilitation with the objective of improving emotion perception deficits may be beneficial for individuals with bvFTD.
2026-05-27 | Comorbidity Between Anti-GAD65 Autoimmune Encephalitis and Behavioral Variant Frontotemporal Dementia: A Case Report.
Background and clinical significance: Autoimmune encephalitis (AE) is an inflammatory brain disorder that manifests through a diverse, unspecific range of neuropsychiatric symptoms. When AE occurs alongside a primary neurodegenerative disorder, the shared symptoms can create a mixed clinical profile, making diagnosis more difficult and potentially postponing effective management and treatment. Case presentation: We describe the case of a 58-year-old female with a one-year history of progressive behavioral and personality changes who presented a subacute confusional state, psychomotor retardation alternating with psychomotor agitation, apathy, visual hallucinations, and motor symptoms. Examination revealed Parkinsonian symptoms and frontal lobe signs. Neuroimaging showed frontotemporal atrophy, while cerebrospinal fluid analysis excluded infection but demonstrated elevated phosphorylated tau, supporting an underlying neurodegenerative process. An electroencephalogram revealed asymmetric temporal slowing without overt epileptiform activity. An initial diagnosis of behavioral variant frontotemporal dementia (bvFTD) was established. Due to rapid clinical deterioration and fluctuating cognition, autoimmune testing was expanded to a full antibody panel, which identified elevated serum anti-glutamic acid decarboxylase 65 (anti-GAD65) antibodies (60 UI/mL, reference range 0-5 UI/mL), establishing a possible coexisting diagnosis of anti-GAD65 autoimmune encephalitis. Initial treatment with intravenous immunoglobulin produced minimal improvement; however, therapeutic plasma exchange led to the remission of psychosis and significant improvement in rigidity, bradykinesia, and attention, with modest amelioration in global cognition. Conclusions: This case highlights the diagnostic challenges posed by overlapping AE and bvFTD clinical pictures, especially when neurodegenerative features obscure an underlying autoimmune process. Early, panel-based neural antibody testing-and consideration of AE even in patients already diagnosed with a major neurocognitive disorder-is critical for avoiding delays in immunotherapy. Prompt recognition and treatment of AE may substantially improve clinical outcomes, even in complex cases with suspected overlap.
2026-06-17 | Diagnosis and management of frontotemporal dementia: a narrative review.
Frontotemporal dementia (FTD) is an umbrella term that encompasses a group of clinically heterogeneous neurodegenerative disorders. It is biologically referred to as Frontotemporal lobar degeneration (FTLD) and is characterized by progressive degeneration of frontal and/or temporal lobes. FTD poses substantial diagnostic and therapeutic challenges due to its heterogeneous clinical presentations, limited biomarker specificity, and overlap with other neurodegenerative and psychiatric diseases. This review synthesizes updated knowledge on the clinical phenotypes of FTD, their prognostic elements, and the underlying genetic and molecular mechanisms. Advances in diagnostic strategies are discussed, including structural and functional neuroimaging, fluid biomarkers, and genetic testing, together with emerging digital and AI-assisted tools that may enhance diagnostic precision. Evidence-based management approaches are examined, alongside the role of multidisciplinary care and caregiver support. Promising therapeutic strategies, including gene-targeted interventions, antisense oligonucleotides, progranulin restoration strategies, immunotherapies, and neuromodulation techniques, are discussed considering recent clinical and preclinical developments. Despite the absence of approved disease-modifying therapies, rapid progress in biomarker development, patient stratification, and personalized approaches offers encouraging prospects for more effective interventions across the FTD spectrum. PubMed/MEDLINE was searched for peer-reviewed articles on FTD diagnosis and management; reference lists of key articles were screened to identify additional sources.
2026-06-04 | Emotion Perception in Behavioral Variant Frontotemporal Dementia and Alzheimer Disease: The Parahippocampal Conundrum.
Emotion perception is the capacity that enables humans to correctly identify the cues that guide interpersonal interactions, forming the basis for social behavior. The parahippocampal cortex may contribute to emotion perception by mediating the associations between context and emotion. Individuals with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) appear to show deficits in this process. Investigating emotion perception impairment in these individuals could offer valuable insights into the underlying neurobiological mechanisms. Participants included a convenience sample of 29 individuals with bvFTD, 25 with AD, and a comparison group of 15 individuals without bvFTD or AD. We performed an extensive neuropsychological assessment and administered the Comprehensive Affect Testing System (CATS) to evaluate the emotion perception process. We then used multiple regression analysis to assess the relationship between CATS main quotient scores and parahippocampal thickness (P ≤ 0.001) obtained from MRI analysis. Participants with bvFTD scored higher on cognitive tests than participants with AD but showed greater deficits in social behavior. On the CATS, participants with bvFTD had lower scores in all 3 emotional quotients (ie, face, prosody, and global), with a statistically significant correlation to parahippocampal thickness. Participants with AD showed milder deficits in all 3 emotion quotients, with no statistically significant correlation to parahippocampal thickness. Our data suggest a significant emotion perception deficit in individuals with bvFTD and support the importance of the parahippocampal gyrus in context-emotion associations. Targeted rehabilitation with the objective of improving emotion perception deficits may be beneficial for individuals with bvFTD.
2026-05-27 | Comorbidity Between Anti-GAD65 Autoimmune Encephalitis and Behavioral Variant Frontotemporal Dementia: A Case Report.
Background and clinical significance: Autoimmune encephalitis (AE) is an inflammatory brain disorder that manifests through a diverse, unspecific range of neuropsychiatric symptoms. When AE occurs alongside a primary neurodegenerative disorder, the shared symptoms can create a mixed clinical profile, making diagnosis more difficult and potentially postponing effective management and treatment. Case presentation: We describe the case of a 58-year-old female with a one-year history of progressive behavioral and personality changes who presented a subacute confusional state, psychomotor retardation alternating with psychomotor agitation, apathy, visual hallucinations, and motor symptoms. Examination revealed Parkinsonian symptoms and frontal lobe signs. Neuroimaging showed frontotemporal atrophy, while cerebrospinal fluid analysis excluded infection but demonstrated elevated phosphorylated tau, supporting an underlying neurodegenerative process. An electroencephalogram revealed asymmetric temporal slowing without overt epileptiform activity. An initial diagnosis of behavioral variant frontotemporal dementia (bvFTD) was established. Due to rapid clinical deterioration and fluctuating cognition, autoimmune testing was expanded to a full antibody panel, which identified elevated serum anti-glutamic acid decarboxylase 65 (anti-GAD65) antibodies (60 UI/mL, reference range 0-5 UI/mL), establishing a possible coexisting diagnosis of anti-GAD65 autoimmune encephalitis. Initial treatment with intravenous immunoglobulin produced minimal improvement; however, therapeutic plasma exchange led to the remission of psychosis and significant improvement in rigidity, bradykinesia, and attention, with modest amelioration in global cognition. Conclusions: This case highlights the diagnostic challenges posed by overlapping AE and bvFTD clinical pictures, especially when neurodegenerative features obscure an underlying autoimmune process. Early, panel-based neural antibody testing-and consideration of AE even in patients already diagnosed with a major neurocognitive disorder-is critical for avoiding delays in immunotherapy. Prompt recognition and treatment of AE may substantially improve clinical outcomes, even in complex cases with suspected overlap.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Behavioral variant of frontotemporal dementia.
3 orphan drug designations for Behavioral variant of frontotemporal dementia.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA | oligonucleotides | EMA | 2018-07-31 | — | Biogen Netherlands B.V. |
Tolfenamic acid | small molecules | EMA | 2016-02-17 | — | RV Developpement |
Methylthioninium | small molecules | EMA | 2010-11-26 | — | Pharma Gateway AB |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.